"Even if the current in vitro results cannot be directly translated into clinical efficacy, it is very interesting that ColdZyme is able to effectively deactivate SARS-CoV-2 in vitro since it constitutes a proof-of-principle that can be taken further into clinical studies.
Thus, the results indicate that ColdZyme can offer a protective barrier against SARS-CoV-2," said Claus Egstrand, Enzymaticaโs Chief Operating Officer. Previous in vitro results made with the same method showed that ColdZyme is effective against another coronavirus, HCoV-229E.